Bicocca Open Archive

Logo unimib boa

Zilioli, V., Gabutti, C., Meli, E., Minga, P., Zancanella, M., Cairoli, R., et al. (2017). Rituximab Plus Bortezomib Still Represents an Effective Treatment Option for Patients with Relapsed or Refractory Mantle Cell Lymphoma. Intervento presentato a: 59th Annual Meeting of the American-Society-of-Hematology (ASH) - DEC 09-12, 2017, Atlanta, GA.

Rituximab Plus Bortezomib Still Represents an Effective Treatment Option for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Cairoli, R;
2017
paper
Hematology
English
59th Annual Meeting of the American-Society-of-Hematology (ASH) - DEC 09-12, 2017
2017
BLOOD
2017
130
S1
5162
none
Zilioli, V., Gabutti, C., Meli, E., Minga, P., Zancanella, M., Cairoli, R., et al. (2017). Rituximab Plus Bortezomib Still Represents an Effective Treatment Option for Patients with Relapsed or Refractory Mantle Cell Lymphoma. Intervento presentato a: 59th Annual Meeting of the American-Society-of-Hematology (ASH) - DEC 09-12, 2017, Atlanta, GA.
02 - Intervento a convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/409601
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
Social impact